Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 3/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.53 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.53 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.53 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.53 |
| ▸ | LTA4H | P09960 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.43 |
| ▸ | HPGD | P15428 | 5/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.40 |
| ▸ | RAB9A | P51151 | 5/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5544362 | 0.79 | CYP2C9 (0.50) | CYP2C9CYP3A4CYP2E1CYP2A6CYP2B6 | |
| SCHEMBL18789395 | 0.76 | CYP3A4 (0.67) | CYP2C9CYP3A4CYP2E1CYP2A6CYP2B6 | |
| SCHEMBL5501090 | 0.74 | CYP2C9 (0.53) | CYP2C9CYP3A4CYP2E1CYP2A6CYP2B6 | |
| SCHEMBL1464252 | 0.73 | — | — | |
| SCHEMBL338810 | 0.73 | LTA4H (0.70) | CYP2C9CYP3A4CYP2E1CYP2A6CYP2B6 | |
| SCHEMBL5499265 | 0.72 | CYP3A4 (0.52) | CYP2C9CYP3A4CYP2E1CYP2A6CYP2B6 | |
| SCHEMBL27373489 | 0.72 | CYP2C9 (0.52) | CYP2C9CYP3A4CYP2E1CYP2A6CYP2B6 | |
| SCHEMBL1357023 | 0.71 | CYP2A6 (0.67) | CYP2C9CYP3A4CYP2E1CYP2A6CYP2B6 | |
| SCHEMBL7455134 | 0.71 | LTA4H (0.67) | CYP2C9CYP3A4CYP2E1CYP2A6CYP2B6 | |
| SCHEMBL4338418 | 0.71 | KCNH2 (0.58) | CYP2C9CYP3A4CYP2E1CYP2A6CYP2B6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230002323-A1 | PROCESS FOR PREPARING [(3-HYDROXYPYRIDINE-2-CARBONYL)AMINO]ALKANOIC ACIDS, ESTERS AND AMIDES | KREOS CAPITAL VII (UK) LIMITED (GB) | 2023-01-05 | — | — | US | disclosed |
| EP-4026829-A1 | PROCESS FOR PREPARING N-[[5-(3-CHLOROPHENYL)-3-HYDROXY-2-PYRIDINYL]CARBONYL]-GLYCINE FROM 5-(3-CHLOROPHENYL)-3-HYDROXY-2-PYRIDINE CARBOXYLIC ACID | Akebia Therapeutics Inc. (US) | 2022-07-13 | — | — | EP | disclosed |
| US-11267785-B2 | Process for preparing [(3-hydroxypyridine-2-carbonyl)amino]alkanoic acids, esters and amides | AKEBIA THERAPEUTICS, INC. (US) | 2022-03-08 | — | — | US | disclosed |
| EP-3683209-B1 | PROCESS FOR PREPARING [(5-(3-CHLOROPHENYL)-3-HYDROXYPYRIDINE-2-CARBONYL)-AMINO]ACETIC ACID FROM 5-((3-CHLOROPHENYL)-3-CHLORO-PYRIDIN-2-YL)-NITRILE, AND PROCESS FOR PREPARING 5-((HALOPHENYL)-3-HALO-PYRIDIN-2-YL)-NITRILE DERIVATIVES | AKEBIA THERAPEUTICS INC (US) | 2021-11-10 | — | — | EP | disclosed |
| US-20210122715-A1 | PROCESS FOR PREPARING [(3-HYDROXYPYRIDINE-2-CARBONYL)AMINO]ALKANOIC ACIDS, ESTERS AND AMIDES | KREOS CAPITAL VII (UK) LIMITED (GB) | 2021-04-29 | — | — | US | disclosed |
| US-10738010-B2 | Process for preparing [(3-hydroxypyridine-2-carbonyl)amino] alkanoic acids, esters and amides | AKEBIA THERAPEUTICS, INC. (US) | 2020-08-11 | — | — | US | disclosed |
| EP-3683209-A1 | PROCESS FOR PREPARING [(5-(3-CHLOROPHENYL)-3-HYDROXYPYRIDINE-2-CARBONYL)-AMINO]ACETIC ACID FROM 5-((3-CHLOROPHENYL)-3-CHLORO-PYRIDIN-2-YL)-NITRILE, AND PROCESS FOR PREPARING 5-((HALOPHENYL)-3-HALO-PYRIDIN-2-YL)-NITRILE DERIVATIVES | Akebia Therapeutics Inc. (US) | 2020-07-22 | — | — | EP | disclosed |
| US-10246416-B2 | Process for preparing [(3-hydroxypyridine-2-carbonyl)amino] alkanoic acids, esters and amides | AKEBIA THERAPEUTICS, INC. (US) | 2019-04-02 | — | — | US | disclosed |
| EP-3293182-A1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | Aerpio Therapeutics, Inc. (US) | 2018-03-14 | — | — | EP | disclosed |
| EP-3290404-A1 | 5-((HALOPHENYL)-3-HALO-PYRIDIN-2-YL)-NITRILE DERIVATIVES AS INTERMEDIATES IN THE PREPARATION OF [(5-(HALOPHENYL)-3-HYDROXYPYRIDINE-2-CARBONYL)-AMINO]ALKANOIC ACID DERIVATIVES | Akebia Therapeutics Inc. (US) | 2018-03-07 | — | — | EP | disclosed |
| US-8106078-B2 | Human protein tyrosine phosphatase inhibitors and methods of use | WARNER CHILCOTT COMPANY, LLC (US) | 2012-01-31 | — | — | US | disclosed |
| US-20110212951-A1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | EyePoint Pharmaceuticals, Inc. | 2011-09-01 | — | — | US | disclosed |
| US-7795444-B2 | Human protein tyrosine phosphatase inhibitors and methods of use | Warner Chilcott Company (US) | 2010-09-14 | — | — | US | disclosed |
| EP-2038265-A2 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | The Procter and Gamble Company (US) | 2009-03-25 | — | — | EP | disclosed |
| WO-2008002570-A2 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | THE PROCTER & GAMBLE COMPANY (US) | 2008-01-03 | — | — | WO | disclosed |
| US-20080004267-A1 | Human protein tyrosine phosphatase inhibitors and methods of use | THE PROCTER & GAMBLE COMPANY (US) | 2008-01-03 | — | — | US | disclosed |
| US-6962923-B2 | Pyrazole compositions | PFIZER INC. (US) | 2005-11-08 | — | — | US | disclosed |
| US-20030232848-A1 | Pyrazole compositions | PFIZER INC. | 2003-12-18 | — | — | US | disclosed |
| US-6573270-B1 | Endothelin receptor antagonists | PFIZER INC. | 2003-06-03 | — | — | US | disclosed |
| EP-1072597-A1 | Pyrazoles and their use as endothelin antagonists | Pfizer Limited (GB) | 2001-01-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10738010-B2 | Process for preparing [(3-hydroxypyridine-2-carbonyl)amino] alkanoic acids, esters and amides | HPD, APEH, P4HA1 | CYP2C9 96/4885CYP3A4 170/4885CYP2E1 108/4885 |
| US-20210122715-A1 | PROCESS FOR PREPARING [(3-HYDROXYPYRIDINE-2-CARBONYL)AMINO]ALKANOIC ACIDS, ESTERS AND AMIDES | HPD, APEH, P4HA1 | CYP2C9 96/4885CYP3A4 170/4885CYP2E1 108/4885 |
| US-20110212951-A1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | PTPRCAP, PTPRC, PPP5C | CYP2C9 4864/4885CYP3A4 4826/4885CYP2E1 4859/4885 |
| US-11267785-B2 | Process for preparing [(3-hydroxypyridine-2-carbonyl)amino]alkanoic acids, esters and amides | HPD, APEH, P4HA1 | CYP2C9 96/4885CYP3A4 170/4885CYP2E1 108/4885 |
| US-20030232848-A1 | Pyrazole compositions | EDNRB, EDNRA, AGTR1 | CYP2C9 887/4885CYP3A4 865/4885CYP2E1 102/4885 |
| US-20230002323-A1 | PROCESS FOR PREPARING [(3-HYDROXYPYRIDINE-2-CARBONYL)AMINO]ALKANOIC ACIDS, ESTERS AND AMIDES | HPD, APEH, P4HA1 | CYP2C9 96/4885CYP3A4 170/4885CYP2E1 108/4885 |
| US-10246416-B2 | Process for preparing [(3-hydroxypyridine-2-carbonyl)amino] alkanoic acids, esters and amides | HPD, APEH, P4HA1 | CYP2C9 96/4885CYP3A4 170/4885CYP2E1 108/4885 |
| US-20080004267-A1 | Human protein tyrosine phosphatase inhibitors and methods of use | PTPRCAP, PTPRC, PPP5C | CYP2C9 4864/4885CYP3A4 4826/4885CYP2E1 4859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.